BGMS on Nasdaq

Cyclacel

American pharmaceutical company

Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1997Founded1

Compare with Greenlane Holdings, Inc., ALLIANCE ENTERTAINMENT HOLDING CORP or Core & Main, or pick any stock.

  • TickerBGMS on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersBerkeley Heights1
  • Websitewww.cyclacel.com
  • Incorporated inDE4
  • Business address200 Connell Drive, Suite 1500, Berkeley Heights, Nj 079224
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20256
-43.8%Return on equity6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Fire Safety Equipment brought in 81% of the revenue Cyclacel broke down this way in fiscal 2025.

  1. Fire Safety Equipment$603.0K681%
  2. Safety Aparel$119.0K616%
  3. Project Supply and Installation$20.0K63%
  4. Maintenance and Servicing$6.0K61%
Products and services by year
Products and services202320242025
Fire Safety Equipment$603.0K
Safety Aparel$119.0K
Project Supply and Installation$20.0K
Maintenance and Servicing$6.0K

Financial statements

Revenue789106$0 in 2025
0$200.0K$400.0K$600.0K2020: $0$020202021: $0$020212022: $0$020222023: $420.0K$420.0K20232024: $43.0K$43.0K2024−90%2025: $0$02025
Operating income11789106-$8.4M in 2025−13% since 2019
-$30.0M-$20.0M-$10.0M02019: -$9.7M-$9.7M20192020: -$10.6M-$10.6M2020+10%2021: -$22.4M-$22.4M2021+111%2022: -$27.7M-$27.7M2022+24%2023: -$25.5M-$25.5M2023−8%2024: -$12.0M-$12.0M2024−53%2025: -$8.4M-$8.4M2025−30%
Net income11789106-$3.0M in 2025−62% since 2019
-$30.0M-$20.0M-$10.0M02019: -$7.8M-$7.8M20192020: -$8.4M-$8.4M2020+8%2021: -$18.5M-$18.5M2021+119%2022: -$21.2M-$21.2M2022+15%2023: -$22.6M-$22.6M2023+6%2024: -$11.2M-$11.2M2024−50%2025: -$3.0M-$3.0M2025−73%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenues$747.0K$43.0K
Cost of sales$609.0K
Research and development$848.0K$6.7M
General and administrative$7.7M$5.4M
Total operating expenses$9.2M$12.0M
Operating loss-$8.4M-$12.0M
Foreign exchange losses$73.0K-$54.0K
Interest income$62.0K$12.0K
Gain on deconsolidation of former subsidiary$4.9M
Other income, net$354.0K$52.0K
Total other income, net$5.4M$10.0K
Loss before taxes-$3.0M-$12.0M
Income tax benefit / (provision)-$7.0K$782.0K
Net loss-$3.0M-$11.2M
Dividend on convertible exchangeable preferred shares-$61.0K
Deemed dividend on warrant exchange-$11.0M
Net loss applicable to common shareholders-$14.1M-$11.2M
Net loss per share - basic (common shareholders)-$6.45-$502.46
Net loss per share - diluted (common shareholders)-$6.45-$502.46
Weighted average common shares outstanding - basic2.2M shares22.3K shares
Weighted average common shares outstanding - diluted2.2M shares22.3K shares

Compare Cyclacel with another company

Leadership

Who has led Cyclacel, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Spiro Rombotis2013–2023
  2. David E. Lazar2025
  3. Wong Sing Ee Doris2025–now

President

  1. Spiro Rombotis2006–2023

Chief financial officer

  1. Paul McBarron2010–2019
  2. Cu Seng Kiu2025–now

Chief operating officer

  1. Paul McBarron2010–2019
200020052010201520202025
Board members and other officers (32)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • The Chief Executive OfficerDatuk Dr. Doris Wong Sing Ee named Mar 25, 202547
  • The Chief Financial OfficerKiu Cu Seng named Mar 25, 202547

Products and brands

  • seliciclib

Listed on Wikidata.1

Acquisitions

After becoming the first European spin-out company to raise over $100 million in private equity, the company had to pull out of a stock market listing in July 2004. Cyclacel completed a reverse merger with Xcyte Therapies in December 2005 to acquire Nasdaq listing. This allowed Cyclacel to raise an additional $45 million in April 2006 through a private placement of stock and warrants.

From Wikipedia’s article on Cyclacel, shared under CC BY-SA 4.0.5

Former names

  • Cyclacel Pharmaceuticals, Inc.Mar 29, 2006 to Sep 12, 20254
  • XCYTE THERAPIES INCDec 22, 2000 to Mar 24, 20064

Timeline

  1. Feb 28, 2025New chief executive Wong Sing Ee Doris becomes CEO15
  2. Jan 7, 2025New chief executive David E. Lazar becomes CEO14
  3. Jan 29, 2013New chief executive Spiro Rombotis becomes CEO16
  4. 1997Founded Founded1

Filings

346 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 95 major events, 81 insider forms, 41 large holders, 5 private raises, 100 other. The latest 20:

  1. Oct 9, 2026424B3 EDGAR
  2. Oct 8, 2026EFFECT EDGAR
  3. Sep 11, 2026S-4/A EDGAR
  4. Aug 21, 2026S-4/A EDGAR
  5. Aug 14, 202610-Q EDGAR
  6. Aug 14, 20268-K EDGAR
  7. Aug 12, 2026SCHEDULE 13G/A EDGAR
  8. Aug 12, 2026SCHEDULE 13G/A EDGAR
  9. Jul 24, 2026S-4/A EDGAR
  10. Jul 1, 20268-K EDGAR
  11. Jun 22, 20268-K EDGAR
  12. Jun 16, 2026S-4 EDGAR
  13. Jun 10, 20268-K EDGAR
  14. Jun 4, 2026425 EDGAR
  15. Jun 4, 20268-K EDGAR
  16. May 15, 202610-Q EDGAR
  17. May 14, 20268-K EDGAR
  18. May 12, 2026SCHEDULE 13G/A EDGAR
  19. May 1, 2026DEFR14A EDGAR
  20. Apr 27, 2026DEF 14A EDGAR

The 346 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 3 buys and 23 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 5, 2025Yap Kim Choy10% ownerSale28,540$1.70$48.5KForm 4
Oct 30, 2025Yap Kim Choy10% ownerSale112,260$1.81$203.2KForm 4
Oct 30, 2025Kua Khai Loon10% ownerSale242,477$1.80$436.5KForm 4
Oct 30, 2025Ong Yee Lung10% ownerSale248,814$1.80$447.9KForm 4
Oct 29, 2025Yap Kim Choy10% ownerSale110,749$1.83$202.7KForm 4
Oct 28, 2025Yap Kim Choy10% ownerSale13,111$1.83$24.0KForm 4
Oct 27, 2025Yap Kim Choy10% ownerSale120,250$2.12$254.9KForm 4
Oct 24, 2025Ong Yee Lung10% ownerSale19,858$1.99$39.5KForm 4
Oct 24, 2025Yap Kim Choy10% ownerSale19,595$1.90$37.2KForm 4
Oct 21, 2025FITTERS Diversified Berhad10% ownerSale92,352$3.01$278.0KForm 4
Oct 20, 2025FITTERS Diversified Berhad10% ownerSale108,107$3.09$334.1KForm 4
Oct 16, 2025Kua Khai Loon10% ownerSale88,204$4.22$372.2KForm 4
Oct 16, 2025FITTERS Diversified Berhad10% ownerSale26,051$5.50$143.3KForm 4
Oct 15, 2025Kua Khai Loon10% ownerSale7,479$5.66$42.3KForm 4
Oct 14, 2025Ong Yee Lung10% ownerSale135,793$6.00$814.8KForm 4
Oct 10, 2025FITTERS Diversified Berhad10% ownerSale51,400$5.26$270.4KForm 4
Oct 8, 2025FITTERS Diversified Berhad10% ownerSale142,000$5.29$751.2KForm 4
Sep 16, 2025Kua Khai Loon10% ownerSale25,000$5.13$128.2KForm 4
Sep 12, 2025Kua Khai Loon10% ownerSale22,251$6.22$138.4KForm 4
Sep 5, 2025Kua Khai Loon10% ownerSale19,054$7.01$133.6KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 21, 2025Raised $1 million in a private offering of equity Form D: 4 investors so far Form D
  2. Feb 14, 2025Filed a private offering of equity Form D: $25 million offered in all Form D
  3. Feb 6, 2025Filed a private offering of equity Form D: 1 investor so far Form D
  4. Nov 14, 2024Raised $2.1 million in a private offering of equity Form D: 1 investor so far Form D
  5. May 2, 2024Raised $8 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC75,240$68.5K0.0%+53,189
Jane Street Group, LLC16,291$14.8K0.0%New
Tower Research Capital LLC (TRC)5,722$5.2K0.0%+1,461
UBS Group AG4,332$3.9K0.0%+2,163
SBI Securities Co., Ltd.701$6380.0%+201
Archer Investment Corp2$20.0%+1
Osaic Holdings, Inc.1$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62